Drugs / MDI-2517
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07220889 Comparator | Nov → Dec 2025 | — | MDI Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06453824 Comparator | May → Nov 2024 | — | MDI Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDI-2517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220889 ↗ |
| Route | Oral | “MDI-2517 tablet, single oral dose or placebo” NCT06453824 ↗ |